Con Kerry Kenneth Stough

Con Kerry Kenneth Stough
Swinburne University of Technology, Co-Director Centre for Human Psychopharmacology & School of Psychology (Faculty of Life and Health Sciences), Australia

Biography

Professor Con Stough is Professor of Cognitive Neurosciences at the Swinburne centre for Psychopharmacology and Professor of Psychology at Swinburne University. The Centre for Psychopharmacology has 20 full time research staff and 20 research students and is a leading research and teaching institute in cognitive neuroscience. He has an extensive track record in research and consulting and has published more than 190 peer reviewed international expert papers in the area of psychological assessment, biological psychology and psychopharmacology. He has also attracted more than 20 million dollars in research grants over the last 10 years from National and International government and Industry sources. Professor Stough is on the advisory panel for the International Society for Intelligence Research and editorial board for the journal Intelligence and other journals and is an invited member of the Neuroscience panel for the World Economic Forum. He has reviewed scientific papers for more than 50 different scientific journals.

Professor Stough is a leading researcher in the area of natural drugs, cognition, mood and the brain. He co-founded the Herbal and Nutraceutical Research Unit at Swinburne University and is past Director of the National Institute of Complementary Medicine (NICM) collaborative research centre in neurocognition and herbal medicines which was part of the Centre for Human Psychopharmacology from 2007-2011. The focus of this unit has been to study the efficacy of cognitive enhancing natural drugs. He has key publications and grants with several natural substances such as Ginkgo Biloba, Bacopa Monniera, DHA and fish oils, St John’s Wort, Pycnogenol, multi vitamins, rye grass, pine needle extract and patented combinations of smart drugs amongst many others. More recent work has been in large pharmacological trials for the prevention of cognitive and brain aging and supplementary treatments for abnormal aging such as Alzheimer’s Dementia.